Operator: Our next question is from the line of Evan Stover with Baird. Please proceed with your question.
Evan Stover: Hey, I’ve got a few. You’ve had some big RIFs recently. At the same time, you’re trying to invest in your sales and your tech headcount as well. Obviously a big change in the stock price, big change in dynamics the last 12 months. Can you talk about employee retention and satisfaction in kind of the areas that are really key and strategic for you and what you’re seeing there?
David Coman: I think the key to employee engagement and retention goes back to the fundamental business idea of Science 37. There really isn’t a company in the clinical trial space that can–is innovative and can provide employees closer access or proximity to patients themselves, and so many people come to Science 37 because of those two reasons, and we continue to see that as the primary driver for retention for the company. We have had a few–you know, the RIF that we announced at the end of the year, I think that always puts some stress, I think, on the organization, and so we’re being really intentional about putting warm blankets on the employees that are still there. We think very highly of them and want to make sure that they understand that they’re highly appreciated, and so we do things every day to make sure that that’s–that that’s understood.
Evan Stover: Okay, fair enough. It’s early on a Monday, I don’t know if I missed this, but you guys had been reiterating kind of the long range runway on EBITDA and cash flow breakeven by the end of ’24. I didn’t hear that. Is that something that you’re stepping away from now? Just curious there.
David Coman: No, not at all. That’s still part of our plan. We still intend to deliver on that.
Evan Stover: Fair enough. Final question from me, CRO channel partnerships, obviously you’ve got several of them, so more important than others, but can you talk to any major shifts, either positively or negatively amongst those channel partnerships in the last 90, 120 days, and I think specifically there was Syneos out there with a Medable partnership renewal, and curious if that’s specifically had or going to have any impact on Science 37.
David Coman: We continue to maintain the relationships that we have announced. One of the great things about Michael Shipton as the new head of the commercial organization is that he comes from the CRO space and believes in that channel tremendously, and so has invested quite a bit in terms of re-energizing that channel for us because he believes that that’s a great area of expansion and opportunity for us.
Evan Stover: All right, that’s it for me. Thank you.
David Coman: Thank you.
Operator: Thank you. At this time, I will turn the floor back over to Steven Halper for closing remarks.
Steven Halper: Thank you Rob, and thank you everyone. We look forward to speaking with you next quarter.
Operator: Thank you to everyone joining us today. This will conclude today’s conference. You may disconnect your lines at this time. Thank you for your participation.
